XENE Xenon Pharmaceuticals
- 41.670
- +1.170+2.89%
Xenon Pharmaceuticals News
Xenon Pharmaceuticals Spotlights XEN1101 Progress
Xenon Pharmaceuticals Announced Two Oral Presentations For XEN1101 Clinical Data At AAN 2024 Annual Meeting
Xenon's Oral Presentations at AANOral Presentation #005 (French et al.) "Interim, Long-term, Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update from an Ongoing Open-l
Express News | Needham Reiterates Buy on Xenon Pharmaceuticals, Maintains $62 Price Target
Express News | Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $65 Price Target
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2024 Bloom
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after l
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 23rd Annual
Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Stifel 2024
Xenon Pharmaceuticals(XENE.US) Director Sells US$95,583.48 in Common Stocks
$Xenon Pharmaceuticals(XENE.US)$ Director GAROFALO ELIZABETH A. sold 2,092 shares of Common Stocks on Mar 8, 2024 at an average price of $45.69 for a total value of $95,583.48.Source: Announcement Wha
Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...
Xenon Pharmaceuticals(XENE.US) Officer Sells US$330.29K in Common Stocks
$Xenon Pharmaceuticals(XENE.US)$ Officer ROBIN SHERRINGTON sold 7,137 shares of Common Stocks on Mar 7, 2024 at an average price of $46.28 for a total value of $330.29K.Source: Announcement What is st
Xenon Pharmaceuticals(XENE.US) Director Sells US$601.61K in Common Stocks
$Xenon Pharmaceuticals(XENE.US)$ Director GANNON STEVEN sold 13,000 shares of Common Stocks on Mar 7, 2024 at an average price of $46.2781 for a total value of $601.61K.Source: Announcement What is st
Xenon Pharmaceuticals Insider Sold Shares Worth $601,615, According to a Recent SEC Filing
Steven Gannon, Director, on March 07, 2024, sold 13,000 shares in Xenon Pharmaceuticals (XENE) for $601,615. Following the Form 4 filing with the SEC, Gannon has control over a total of 2,000 shares o
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Leerink Partners
Buy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progress
Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Worth US$46.8 Based On Its Intrinsic Value?
Key Insights Xenon Pharmaceuticals' estimated fair value is US$38.06 based on 2 Stage Free Cash Flow to Equity Xenon Pharmaceuticals' US$46.84 share price signals that it might be 23% overvalued O
Earnings Call Summary | Xenon Pharmaceuticals(XENE.US) Q4 2023 Earnings Conference
The following is a summary of the Xenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcript:Financial Performance:Xenon Pharmaceuticals reported a year-end cash balance of $930.9 million comp
Xenon Pharmaceuticals Price Target Raised to $51.00/Share From $46.00 by Wedbush
Xenon Pharmaceuticals Price Target Raised to $51.00/Share From $46.00 by Wedbush
Xenon Pharmaceuticals Is Maintained at Buy by Needham
Xenon Pharmaceuticals Is Maintained at Buy by Needham
Analysis
Price Target
No Data
